Greenwich Lifesciences Financials
| GLSI Stock | USD 11.72 0.22 1.84% |
Greenwich | Build AI portfolio with Greenwich Stock |
Understanding current and past Greenwich Lifesciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Greenwich Lifesciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Greenwich Lifesciences' assets may result in an increase in income on the income statement.
Greenwich Lifesciences Stock Summary
Greenwich Lifesciences competes with Day One, Immutep, Kaixin Auto, Mereo BioPharma, and NLS Pharmaceutics. Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.Specialization | Healthcare, Biotechnology |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US3968791083 |
| CUSIP | 396879108 |
| Location | Texas; U.S.A |
| Business Address | Building 14, Stafford, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | greenwichlifesciences.com |
| Phone | 832 819 3232 |
| Currency | USD - US Dollar |
Greenwich Lifesciences Key Financial Ratios
| Return On Equity | -5.15 | ||||
| Return On Asset | -2.54 | ||||
| Target Price | 39.0 | ||||
| Beta | 3.16 |
Greenwich Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Greenwich Lifesciences's current stock value. Our valuation model uses many indicators to compare Greenwich Lifesciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Greenwich Lifesciences competition to find correlations between indicators driving Greenwich Lifesciences's intrinsic value. More Info.Greenwich Lifesciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Greenwich Lifesciences' earnings, one of the primary drivers of an investment's value.Greenwich Lifesciences Systematic Risk
Greenwich Lifesciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Greenwich Lifesciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Greenwich Lifesciences correlated with the market. If Beta is less than 0 Greenwich Lifesciences generally moves in the opposite direction as compared to the market. If Greenwich Lifesciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Greenwich Lifesciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Greenwich Lifesciences is generally in the same direction as the market. If Beta > 1 Greenwich Lifesciences moves generally in the same direction as, but more than the movement of the benchmark.
About Greenwich Lifesciences Financials
What exactly are Greenwich Lifesciences Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Greenwich Lifesciences' income statement, its balance sheet, and the statement of cash flows. Potential Greenwich Lifesciences investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Greenwich Lifesciences investors may use each financial statement separately, they are all related. The changes in Greenwich Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Greenwich Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Greenwich Lifesciences August 5, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Greenwich Lifesciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Greenwich Lifesciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Greenwich Lifesciences based on widely used predictive technical indicators. In general, we focus on analyzing Greenwich Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Greenwich Lifesciences's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.91 | |||
| Information Ratio | 0.0821 | |||
| Maximum Drawdown | 16.78 | |||
| Value At Risk | (5.27) | |||
| Potential Upside | 7.66 |
Complementary Tools for Greenwich Stock analysis
When running Greenwich Lifesciences' price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |